TRPM2 Antibody - #DF7533

Figure 1| Verification of TRMP2 knockdown efficiency. (B) TRPM2 protein expression. TRPM2 expression was normalized to β-actin expression based on grayscale analysis. Data are expressed as the mean ± standard deviation (SD)(n = 6; one-way analysis of variance followed by Student-Newman-Keuls post hoc test). *P < 0.05, vs. shRNA-NC group. NC: Normal control; OGD:oxygen-glucose deprivation; PC12: pheochromocytoma; TRPM2: transient receptor potential melastatin 2.

Fig. 1.|Expression of TRPM2 (B) was up-regulated after glucose and oxygen deprivation, and reached the maximum value after 12 h. Scale bar, 50 µm. Data presented as means ± SD and compared by one-way ANOVA and SNK method. *P < 0.05, **P < 0.01, ***P < 0.001.

FIGURE 7 Expression and co-localization of NR2A and transient receptor potential melastatin-related 2 (TRPM2) in the rat hippocampus. (A) Protein amounts of TRPM2 in the hippocampal dorsal CA1 region of rats. (B) Protein amounts of NR2A in the hippocampal dorsal CA1 region of rats. (C) Effects of Pur on NR2A and TRPM2 co-localization in the hippocampal dorsal CA1 region, examined by immunofluorescence double staining. Representative micrographs are shown at ×200. Results were mean ± SEM (n = 6). **P < 0.01 vs. Sham; ##P < 0.01 vs. BCCAO; $$P < 0.01 vs. BCCAO + Pur (150 mg/kg/day).

FIGURE 7 Expression and co-localization of NR2A and transient receptor potential melastatin-related 2 (TRPM2) in the rat hippocampus. (A) Protein amounts of TRPM2 in the hippocampal dorsal CA1 region of rats. (B) Protein amounts of NR2A in the hippocampal dorsal CA1 region of rats. (C) Effects of Pur on NR2A and TRPM2 co-localization in the hippocampal dorsal CA1 region, examined by immunofluorescence double staining. Representative micrographs are shown at ×200. Results were mean ± SEM (n = 6). **P < 0.01 vs. Sham; ##P < 0.01 vs. BCCAO; $$P < 0.01 vs. BCCAO + Pur (150 mg/kg/day).

Figure 2 Effects of QFZS on TRPM2 expression A: the immunohistochemistry staining of TRPM2, A1-A4: images of control (A1), model (A2), Lose-dose QFZS (A3), High-dose QFZS(A4) (× 1); A5-A8: images of control (A5), model (A6), Lose-dose QFZS (A7), High-dose QFZS(A8) (× 200, bar = 100 μm); A9-A12: images of control (A9), model (A10), Lose-dose QFZS (A11), High-dose QFZS(A12) (× 400, bar = 50 μm). B: Western blotting representative images of TRPM2 respective quantification in the hypothalamus; C: protein expression levels of TRPM2. Control group: sham operated; Model group: Yeast-induced fever model without treatment; Positive group: Yeast-induced fever model with Aspirin (100 mg/kg); Lose-dose QFZS group: Yeast-induced fever model with low-dose QFZS (2.82 g/kg); High-dose QFZS group: Yeast-induced fever model with high-dose QFZS (5.64 g/kg). TRPM2: transient receptor potential melastatin 2; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; QFZS: Qingfei Zhisou oral liquid. Data represent the mean ± standard deviation using one-way analysis of variance (n = 5). Compared with the sham group, aP < 0.05; compared with the model group, bP < 0.05.